Mingzi Li Selected Research

Proteins (Proteins, Gene)

1/2024	ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
1/2021	Serum oxidized low density lipoprotein serves as a mediator for the inverse relationship between serum d-ribose and cognitive performance in type 2 diabetic patients.
1/2018	ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mingzi Li Research Topics

Disease

5	Stroke (Strokes) 04/2024 - 01/2013
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2024 - 01/2018
4	Type 2 Diabetes Mellitus (MODY) 02/2023 - 09/2017
3	Neoplasms (Cancer) 01/2022 - 01/2018
2	Hypoglycemia (Reactive Hypoglycemia) 01/2023 - 01/2019
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 07/2021
2	Body Weight (Weight, Body) 11/2020 - 10/2019
2	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2018
2	Hypertension (High Blood Pressure) 01/2020 - 01/2013
1	Kidney Neoplasms (Kidney Cancer) 01/2024
1	Insulin Resistance 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2022
1	Inflammation (Inflammations) 01/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Cognitive Dysfunction 01/2019
1	Carcinogenesis 01/2018
1	Convalescence 01/2018
1	Hyperinsulinism (Hyperinsulinemia) 01/2018
1	Ischemic Stroke 12/2017
1	Coronary Disease (Coronary Heart Disease) 01/2013
1	Renal Hypertension 01/2013
1	Diabetes Mellitus 01/2013

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2018
3	Blood Glucose (Blood Sugar)IBA 02/2023 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2018
1	Sunitinib (Sutent)FDA Link 01/2024
1	Insulin (Novolin)FDA Link 01/2023
1	asciminibIBA 01/2022
1	Circular RNAIBA 01/2022
1	ChromatinIBA 01/2022
1	DeoxyuridineIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Bovine Serum AlbuminIBA 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 01/2022
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2022
1	Kruppel-Like Transcription Factors (Kruppel-Like Factors)IBA 01/2022
1	BuffersIBA 07/2021
1	Sulfhydryl Compounds (Thiols)IBA 01/2021
1	Ribose (D-Ribose)IBA 01/2021
1	Receptor for Advanced Glycation End ProductsIBA 01/2021
1	Advanced Oxidation Protein Products (AOPP)IBA 01/2021
1	Advanced Glycation End ProductsIBA 01/2021
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021
1	oxidized low density lipoproteinIBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 11/2020
1	NAD (NADH)IBA 01/2020
1	Long Noncoding RNAIBA 01/2020
1	LDL CholesterolIBA 10/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019
1	ORALIT (ORS)IBA 01/2019
1	HomocysteineIBA 01/2018
1	ArrestinsIBA 01/2018
1	ApolipoproteinsIBA 12/2017
1	Glucose (Dextrose)FDA LinkGeneric 12/2017
1	Apolipoproteins E (ApoE)IBA 12/2017
1	danaparoid (Orgaran)FDA Link 12/2017
1	CholesterolIBA 01/2013
1	Triglycerides (Triacylglycerol)IBA 01/2013
1	Uric Acid (Urate)IBA 01/2013
1	LipidsIBA 01/2013
1	CreatinineIBA 01/2013

Therapy/Procedure

5	Glycemic Control 01/2022 - 09/2017
3	Therapeutics 04/2024 - 11/2021